Literature DB >> 2931415

The pharmacokinetics of ciprofloxacin in patients with impaired renal function.

J Boelaert, Y Valcke, M Schurgers, R Daneels, M Rosseneu, M T Rosseel, M G Bogaert.   

Abstract

Pharmacokinetics of ciprofloxacin after single oral administration of 250 mg were studied in patients with and without renal failure. Ciprofloxacin concentrations were measured by HPLC. The elimination half-life was 8.7 +/- 0.9 h (mean +/- S.E.M.) in six renal failure patients not on haemodialysis, as compared to 4.4 +/- 0.2 h in six patients with normal renal function. The urinary recovery of unchanged ciprofloxacin was 5.3 +/- 1.7% of dose over 24 h in the renal failure patients, as compared to 37.0 +/- 3.7% in the patients with normal renal function. In haemodialysis patients, the half-life was 5.8 +/- 0.9 h on an interdialysis day, and 3.2 +/- 0.4 h during haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931415     DOI: 10.1093/jac/16.1.87

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Influence of haemodialysis on the pharmacokinetics of ciprofloxacin.

Authors:  J P Samsom
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

4.  Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.

Authors:  G L Drusano; M Weir; A Forrest; K Plaisance; T Emm; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.

Authors:  G D Fang; C Brennen; M Wagener; D Swanson; M Hilf; L Zadecky; J DeVine; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.

Authors:  T C Gasser; S C Ebert; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

10.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.